379 related articles for article (PubMed ID: 31267559)
1. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.
Zhao J; Zhong S; Niu X; Jiang J; Zhang R; Li Q
Scand J Immunol; 2019 Nov; 90(5):e12804. PubMed ID: 31267559
[TBL] [Abstract][Full Text] [Related]
2. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Barkal AA; Weiskopf K; Kao KS; Gordon SR; Rosental B; Yiu YY; George BM; Markovic M; Ring NG; Tsai JM; McKenna KM; Ho PY; Cheng RZ; Chen JY; Barkal LJ; Ring AM; Weissman IL; Maute RL
Nat Immunol; 2018 Jan; 19(1):76-84. PubMed ID: 29180808
[TBL] [Abstract][Full Text] [Related]
3. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
4. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller T; Münnich IA; Windisch R; Hilger P; Schewe DM; Humpe A; Kellner C
Front Immunol; 2023; 14():1240275. PubMed ID: 37781391
[TBL] [Abstract][Full Text] [Related]
5. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
6. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
7. Is CD47 an innate immune checkpoint for tumor evasion?
Liu X; Kwon H; Li Z; Fu YX
J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L
EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
10. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
11. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
12. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
13. β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system.
Ardeniz Ö; Unger S; Onay H; Ammann S; Keck C; Cianga C; Gerçeker B; Martin B; Fuchs I; Salzer U; İkincioğulları A; Güloğlu D; Dereli T; Thimme R; Ehl S; Schwarz K; Schmitt-Graeff A; Cianga P; Fisch P; Warnatz K
J Allergy Clin Immunol; 2015 Aug; 136(2):392-401. PubMed ID: 25702838
[TBL] [Abstract][Full Text] [Related]
14. Targeting macrophages in hematological malignancies: recent advances and future directions.
Li W; Wang F; Guo R; Bian Z; Song Y
J Hematol Oncol; 2022 Aug; 15(1):110. PubMed ID: 35978372
[TBL] [Abstract][Full Text] [Related]
15. Cross-Activation of Hemichannels/Gap Junctions and Immunoglobulin-Like Domains in Innate-Adaptive Immune Responses.
Meng JH; Chen CX; Ahmadian MR; Zan H; Luo KJ; Jiang JX
Front Immunol; 2022; 13():882706. PubMed ID: 35911693
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for RIFIN-mediated activation of LILRB1 in malaria.
Harrison TE; Mørch AM; Felce JH; Sakoguchi A; Reid AJ; Arase H; Dustin ML; Higgins MK
Nature; 2020 Nov; 587(7833):309-312. PubMed ID: 32650338
[TBL] [Abstract][Full Text] [Related]
17. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
18. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
19. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
20. Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?
Lentz RW; Colton MD; Mitra SS; Messersmith WA
Mol Cancer Ther; 2021 Jun; 20(6):961-974. PubMed ID: 33850005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]